AGN,UPDATE 4-Valeant boosts $53.8 bln Allergan bid as Ackman opts for stock May 30 Valeant Pharmaceuticals International Inc   said on Friday it would boost its takeover bid for Botox-maker Allergan Inc for the second time this week, contingent on the two sides negotiating. 
JNJ,Pharmacyclics, J&J; drug shown to improve leukemia survivalUPDATE 1-Pharmacyclics, J&J; drug shown to improve leukemia survival CHICAGO, May 31 A new drug for the most common form of leukemia in adults  improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.  UPDATE 1-Pharmacyclics, J&J; drug shown to improve leukemia survival CHICAGO, May 31 A new drug for the most common form of leukemia in adults  improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday. CHICAGO, May 31 A new drug for the most common form of leukemia in adults  improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.UPDATE 1-Pharmacyclics, J&J; drug shown to improve leukemia survival CHICAGO, May 31 A new drug for the most common form of leukemia in adults  improves survival for patients whose disease has worsened despite standard treatment, according to late-stage study findings released on Saturday.  
PFE,Two experimental AstraZeneca drugs show promise in ovarian cancer May 31 A combination of two drugs developed by AstraZeneca Plc, olaparib and cediranib, was shown in a mid-stage study to nearly double the length of time certain ovarian cancer patients lived without their disease getting worse. 
SIG,Three funds to seek appraisal of Zale shares over Signet deal -WSJ May 30 Three funds that voted against or did not vote for Zale Corp's merger with rival Signet Jewelers Ltd plan to seek an independent valuation of their shares from a judge, the Wall Street Journal reported, citing people familiar with the matter. 
